logo
Plus   Neg
Share
Email

Amgen Terminates Collaboration With Cytokinetics On Omecamtiv Mecarbil And AMG 594

Cytokinetics Inc. (CYTK) said Monday that Amgen has elected to terminate the Collaboration and Option Agreement, dated December 20, 2006 between the companies and end its collaboration with Cytokinetics, effective May 20, 2021. Amgen plans to transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to Cytokinetics.

Cytokinetics said it will have no trailing royalty payment obligations to Amgen for either omecamtiv mecarbil or AMG 594.

Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase 3 cardiovascular outcomes clinical trial.

AMG 594, a novel mechanism cardiac troponin activator, is in Phase 1 development for HFrEF and other types of heart failure.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT